370 related articles for article (PubMed ID: 30846679)
21. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
22. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
[TBL] [Abstract][Full Text] [Related]
23. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
24. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
[TBL] [Abstract][Full Text] [Related]
25. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
26. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Neben K; Lokhorst HM; Jauch A; Bertsch U; Hielscher T; van der Holt B; Salwender H; Blau IW; Weisel K; Pfreundschuh M; Scheid C; Dührsen U; Lindemann W; Schmidt-Wolf IG; Peter N; Teschendorf C; Martin H; Haenel M; Derigs HG; Raab MS; Ho AD; van de Velde H; Hose D; Sonneveld P; Goldschmidt H
Blood; 2012 Jan; 119(4):940-8. PubMed ID: 22160383
[TBL] [Abstract][Full Text] [Related]
27. Imaging flow cytometric detection of del(17p) in bone marrow and circulating plasma cells in multiple myeloma.
Mincherton TI; Lam SJ; Clarke SE; Hui HYL; Malherbe JAJ; Chuah HS; Sidiqi MH; Fuller KA; Erber WN
Int J Lab Hematol; 2024 Jun; 46(3):495-502. PubMed ID: 38379463
[TBL] [Abstract][Full Text] [Related]
28. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
[TBL] [Abstract][Full Text] [Related]
29. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
30. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
[TBL] [Abstract][Full Text] [Related]
31. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
[TBL] [Abstract][Full Text] [Related]
32. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
33. Autologous stem cell transplantation in the treatment of multiple myeloma with 17p deletion.
Czyż J; Jurczyszyn A; Szudy-Szczyrek A; Koclęga A; Jachalska A; Dzierżak-Mietła M; Puła B; Jamroziak K; Usnarska-Zubkiewicz L; Gil L; Romejko-Jarosińska J; Waszczuk-Gajda A
Pol Arch Intern Med; 2020 Feb; 130(2):106-111. PubMed ID: 31933484
[TBL] [Abstract][Full Text] [Related]
34. Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma.
Gupta R; Kaur G; Kumar L; Rani L; Mathur N; Sharma A; Dahiya M; Shekhar V; Khan S; Mookerjee A; Sharma OD
Ann Hematol; 2018 Dec; 97(12):2447-2454. PubMed ID: 30056581
[TBL] [Abstract][Full Text] [Related]
35. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.
Paul E; Sutlu T; Deneberg S; Alici E; Björkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
Oncol Rep; 2009 Jul; 22(1):137-42. PubMed ID: 19513515
[TBL] [Abstract][Full Text] [Related]
36. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
Wang Y; Li Q; Xing S; Zhang H; Li D
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
[TBL] [Abstract][Full Text] [Related]
37. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.
Giri S; Huntington SF; Wang R; Zeidan AM; Podoltsev N; Gore SD; Ma X; Gross CP; Davidoff AJ; Neparidze N
Blood Adv; 2020 May; 4(10):2245-2253. PubMed ID: 32442299
[TBL] [Abstract][Full Text] [Related]
38. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
39. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
Jiang N; Qi C; Trieu Y; Reece D; Chang H
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
[TBL] [Abstract][Full Text] [Related]
40. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J; Goyal S; Chen Z; Boise LH; Lonial S; Nooka AK; Kaufman JL
Blood Cancer J; 2019 Nov; 9(12):94. PubMed ID: 31767829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
